Business
Puma Biotechnology to Present at TD Cowen’s 46th Annual Health Care Conference
LOS ANGELES, February 23, 2026--Puma Biotechnology CEO & President Alan Auerbach will provide a corporate overview at the TD Cowen Health Care Conference on March 2 at 2:30 pm ET.
About this update from Puma Se
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":2400,"height":800,"url":"https://media.zenfs.com/en/business-wire.com/fbac512f171ed69d9fbf2933e2c9b995"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/2fzhJ7J_Fd74p65a9aZ59A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMyMDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/fbac512f171ed69d9fbf2933e2c9b995","width":960,"height":320},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/o4lHx1ll5QrrpPNV7jS5kg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD04MDA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/fbac512f171ed69d9fbf2933e2c9b995","width":1200,"height":400}},"lazy":false},{"type":"text","content":"LOS ANGELES, February 23, 2026--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder, will provide an overview of Puma at 2:30 p.m. ET on Monday, March 2, at the TD Cowen 46th Annual Health Care Conference. The conference will be held March 2–4, 2026 at the Boston Marriott Copley Place in Boston.","length":421,"tagName":"p"},{"type":"text","content":"A live webcast of the conference call and presentation slides may be accessed on the Investors section of the Puma Biotechnology website at https://www.pumabiotechnology.com. The presentation will be archived on the website and available for 30 days.","length":250,"tagName":"p"},{"type":"text","content":"About Puma Biotechnology","length":24,"tagName":"p"},{"type":"text","content":"Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licensed the global development and commercialization rights to PB272 (neratinib, oral) in 2011. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have rece...